Related Experiment Video

Updated: Jun 8, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Biological considerations and clinical applications of new HER2-targeted agents

Gerald M Higa1, Vikramjit Singh, Jame Abraham

  • 1Schools of Pharmacy and Medicine, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506-9162, USA.

Expert Review of Anticancer Therapy
|September 15, 2010
PubMed

Insights

The human epidermal growth factor receptor 2 (HER2) is a key oncology target. Novel agents are being developed to overcome resistance to HER2-targeted therapies in patients with HER2-positive cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The human epidermal growth factor receptor 2 (HER2) oncogene is a well-established target in cancer therapy.
  • HER2 amplification is linked to aggressive tumor phenotypes and poor prognosis in certain cancers.
  • Anti-HER2 therapies have improved outcomes for HER2-positive breast cancer patients, but resistance remains a challenge.

Purpose of the Study:

  • To review the biology of HER2 and its role in cancer.
  • To discuss novel therapeutic agents targeting HER2 in patients who have progressed on existing therapies.
  • To explore strategies for overcoming treatment resistance in HER2-driven cancers.

Main Methods:

  • Review of preclinical and clinical studies on HER2 biology and targeted therapies.
  • Analysis of data from ongoing clinical trials of novel anti-HER2 agents.
  • Discussion of mechanisms of resistance to HER2-targeted treatments.

Main Results:

  • HER2 overexpression drives tumor growth and is a validated therapeutic target.
  • Despite initial success, many patients develop resistance to current HER2-targeted treatments.
  • Several novel agents are in clinical development to address treatment resistance and disease progression.

Conclusions:

  • Targeting HER2 has revolutionized the treatment of HER2-positive cancers.
  • Understanding HER2 biology is crucial for developing effective therapeutic strategies.
  • Novel HER2-targeting agents hold promise for improving outcomes in patients with refractory or progressive disease.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...